A latest report has been added to the wide database of Rheumatology Therapeutics Market by Infinium Global Research. This report
studies the Rheumatology Therapeutics Market by Drug Class (disease modifying anti-rheumatic, nonsteroidal anti-inflammatory,
corticosteroids, uric acid drugs), by Disease Indication (rheumatoid arthritis, osteoarthritis, gout, psoriatic arthritis, ankylosing
spondylitis), and by Distribution Channel (hospital, retail, online pharmacy) market status and outlook of global and major regions,
from manufacturers, and end industries. The objective of the study is to identify market sizes of different segments & countries in
recent years and to forecast the values for the next six years. Rheumatology Therapeutics Market provides opportunities in micro
markets for stakeholders to invest along with the detailed analysis of competitive landscape, latest trends, and product offerings of the
major companies in the Rheumatology Therapeutics Market. According to the report the Global Rheumatology Therapeutics Market is
projected to grow at a CAGR of 2.52%in terms of value over the period of 2018-2024.
Market Insight
Ardea Biosciences received approval from FDA for Duzallo (lesinurad and allopurinol) which help to treatment of hyperuricemia
associated with gout. According to FDA, Duzallo combination of two medications with complementary mechanisms of action with
contains lesinurad, a uric acid reabsorption inhibitor, and allopurinol, a xanthine oxidase inhibitor. Duzallo lowers serum uric acid levels
by increasing excretion and inhibiting production of uric acid. Duzallo is specifically indicated for the treatment of hyperuricemia
associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of
allopurinol alone. Recently, Sanofi and Regeneron announce FDA approval of Kevzara (sarilumab) for the treatment of moderately to
severely active rheumatoid arthritis in adult patients.
Kevzara is an interlukin-6 receptor antibody, which is used for treating adult patients with moderate to severe stages of active
rheumatoid arthritis (RA) who have shown indecisive response or intolerance to one or more non-biologic or biologic DMARDs i.e.
Disease Modifying Anti Rheumatic Drugs. The development of new drugs which help to treat these diseases more effectively called
biologics, or disease modifying agents. The increasing elderly population worldwide and approval of new drugs for treating various
rheumatic diseases, the growing awareness among society about the treatment of rheumatic diseases and lucrative environment of
the treatment has driven the growth of the market. Additionally high funding for research and development activities is likely to boost
the growth of the market.